Diagnosis and treatment of adults with community-acquired pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 200, Issue 7, 2019, Pages E45-E67

  Metlay, Joshua P ^a,b   Waterer, Grant W ^c   Long, Ann C ^d,e   Anzueto, Antonio ^f   Brozek, Jan ^g,h   Crothers, Kristina ⁱ   Cooley, Laura A ^j,k   Dean, Nathan C ^l,m   Fine, Michael J ⁿ   Flanders, Scott A ^o   Griffin, Marie R ^h   Metersky, Mark L ^p   Musher, Daniel M ^q,r   Restrepo, Marcos I ^d,e   Whitney, Cynthia G ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^j INTERMOUNTAIN MEDICAL CENTER   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^m UNIVERSITY OF PITTSBURGH   (United States)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

^o VANDERBILT UNIVERSITY   (United States)

^p UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^q MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^r BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Community acquired pneumonia; Patient management; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; PROCALCITONIN; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BETA LACTAM; MACROLIDE;

ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIUM CULTURE; BLOOD CULTURE; CLINICAL DECISION MAKING; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC IMAGING; EVIDENCE BASED PRACTICE; FOLLOW UP; GRAM STAINING; HOSPITAL CARE; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INTENSIVE CARE UNIT; LEGIONELLA; LOWER RESPIRATORY TRACT; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OUTPATIENT CARE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TELEMETRY; THORAX RADIOGRAPHY; AMBULATORY CARE; BACTERIAL PNEUMONIA; CELL CULTURE TECHNIQUE; CHLAMYDOPHILA INFECTION; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED INFECTION; HAEMOPHILUS INFECTION; HOSPITALIZATION; LEGIONNAIRE DISEASE; METABOLISM; MORAXELLACEAE INFECTION; MYCOPLASMA PNEUMONIA; SEVERITY OF ILLNESS INDEX; SPUTUM; STAPHYLOCOCCAL PNEUMONIA; STREPTOCOCCUS PNEUMONIA; UNITED STATES; URINE;

ADULT; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BETA-LACTAMS; BLOOD CULTURE; CHLAMYDOPHILA INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; CULTURE TECHNIQUES; DRUG THERAPY, COMBINATION; HAEMOPHILUS INFECTIONS; HOSPITALIZATION; HUMANS; LEGIONELLOSIS; MACROLIDES; MORAXELLACEAE INFECTIONS; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, STAPHYLOCOCCAL; RADIOGRAPHY, THORACIC; SEVERITY OF ILLNESS INDEX; SPUTUM; UNITED STATES;

EID: 85072774669     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201908-1581ST     Document Type: Article

References (216)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
2. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400.
3. Metlay JP, Kapoor WN, Fine MJ. Does this patient have communityacquired pneumonia- Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-1445.
4. Sato T, Aoshima M, Ohmagari N, Tada H, Chohnabayashi N. Usefulness of sputum Gram staining in community-acquired pneumonia [in Japanese]. Nihon Kokyuki Gakkai Zasshi 2002;40:558-563.
5. Shariatzadeh MR, Marrie TJ. Does sputum culture affect the management and/or outcome of community-acquired pneumonia-. East Mediterr Health J 2009;15:792-799.
6. Signori LG, Ferreira MW, Vieira LC, Muller KR, Mattos WL. Sputum examination in the clinical management of community-acquired pneumonia [in Portuguese]. J Bras Pneumol 2008;34:152-158.
7. Uematsu H, Hashimoto H, Iwamoto T, Horiguchi H, Yasunaga H. Impact of guideline-concordant microbiological testing on outcomes of pneumonia. Int J Qual Health Care 2014;26:100-107.
8. Lidman C, Burman LG, Lagergren A, Ortqvist A. Limited value of routine microbiological diagnostics in patients hospitalized for communityacquired pneumonia. Scand J Infect Dis 2002;34:873-879.
9. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-348.
10. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: A prospective randomised study. Thorax 2005;60:672-678.
11. Ewig S, Torres A, Angeles Marcos M, Angrill J, RañóA, de Roux A, et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002;20: 1254-1262.
12. Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-1492.
13. García-Vázquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004;164:1807-1811.
14. Lévy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988;93:43-48.
15. Miyashita N, Shimizu H, Ouchi K, Kawasaki K, Kawai Y, Obase Y, et al. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 2008;14:CR171-CR176.
16. Rosón B, CarratalàJ, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000;31:869-874.
17. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Jansen HM, Boersma WG. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:241-249.
18. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputumand sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004;39:165-169.
19. McCauley LM, Webb BJ, Sorensen J, Dean NC. Use of tracheal aspirate culture in newly intubated patients with community-onset pneumonia. Ann Am Thorac Soc 2016;13:376-381.
20. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084.
21. Benenson RS, Kepner AM, Pyle DN II, Cavanaugh S. Selective use of blood cultures in emergency department pneumonia patients. J Emerg Med 2007;33:1-8.
22. Dedier J, Singer DE, Chang Y, Moore M, Atlas SJ. Processes of care, illness severity, and outcomes in the management of communityacquired pneumonia at academic hospitals. Arch Intern Med 2001; 161:2099-2104.
23. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: A prospective observational study. Chest 2003;123:1142-1150.
24. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
25. Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 1999;116:1278-1281.
26. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:342-347.
27. Costantini E, Allara E, Patrucco F, Faggiano F, Hamid F, Balbo PE. Adherence to guidelines for hospitalized community-acquired pneumonia over time and its impact on health outcomes and mortality. Intern Emerg Med 2016;11:929-940.
28. Falguera M, Ruiz-González A, Schoenenberger JA, Touzón C, Gázquez I, Galindo C, et al. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with communityacquired pneumonia. Thorax 2010;65:101-106.
29. Piso RJ, Iven-Koller D, Koller MT, Bassetti S. The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment. Swiss Med Wkly 2012;142:w13679.
30. Garrison LE, Kunz JM, Cooley LA, Moore MR, Lucas C, Schrag S, et al. Vital signs: Deficiencies in environmental control identified in outbreaks of legionnaires' disease. North America, 2000-2014. MMWR Morb Mortal Wkly Rep 2016;65:576-584.
31. Dooling KL, Toews KA, Hicks LA, Garrison LE, Bachaus B, Zansky S, et al. Active bacterial core surveillance for legionellosis: United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2015;64:1190-1193.
32. Uyeki TM. Preventing and controlling influenza with available interventions. N Engl J Med 2014;370:789-791.
33. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM Jr, Fry AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2018;68:e1-e47.
34. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619-1628.
35. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
36. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;(9): CD007498.
37. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65:183-190.
38. Kamat IS, Ramachandran V, Eswaran H, Abers MS, Musher DM. Low procalcitonin, community acquired pneumonia, and antibiotic therapy. Lancet Infect Dis 2018;18:496-497.
39. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with communityacquired pneumonia. N Engl J Med 1997;336:243-250.
40. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003;58:377-382.
41. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118: 384-392.
42. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG; CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749-755.
43. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: A randomized, controlled trial. Ann Intern Med 2005;143:881-894.
44. CarratalàJ, Fernández-SabéN, Ortega L, CastellsaguéX, Rosón B, Dorca J, et al. Outpatient care compared with hospitalization for community-acquired pneumonia: A randomized trial in low-risk patients. Ann Intern Med 2005;142:165-172.
45. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, et al. Safely increasing the proportion of patients with communityacquired pneumonia treated as outpatients: An interventional trial. Arch Intern Med 1998;158:1350-1356.
46. Jo S, Kim K, Jung K, Rhee JE, Cho IS, Lee CC, et al. The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia. J Emerg Med 2012;42:133-138.
47. Julián-Jiménez A, Palomo de los Reyes MJ, Parejo Miguez R, Laín-Terés N, Cuena-Boy R, Lozano-Ancín A. Improved management of community-acquired pneumonia in the emergency department. Arch Bronconeumol 2013;49:230-240.
48. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, et al.; Pneumocom Study Investigators. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: A multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007;44:41-49.
49. Labarere J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a clusterrandomized trial. J Gen Intern Med 2006;21:745-752.
50. Marrie TJ, Huang JQ. Low-risk patients admitted with communityacquired pneumonia. Am J Med 2005;118:1357-1363.
51. Dean NC, Jones BE, Jones JP, Ferraro JP, Post HB, Aronsky D, et al. Impact of an electronic clinical decision support tool for emergency department patients with pneumonia. Ann Emerg Med 2015;66: 511-520.
52. Richards DA, Toop LJ, Epton MJ, McGeoch GR, Town GI, Wynn-Thomas SM, et al. Home management of mild to moderately severe community-acquired pneumonia: A randomised controlled trial. Med J Aust 2005;183:235-238.
53. Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004;125:2140-2145.
54. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc 2012;60:2137-2143.
55. MDCalc. PSI/PORT score: Pneumonia severity index for CAP [accessed 2019 Sept 8]. Available from: Https://www.mdcalc.com/ psi-port-score-pneumonia-severity-index-cap.
56. Jones BE, Jones J, Bewick T, Lim WS, Aronsky D, Brown SM, et al. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 2011;140:156-163.
57. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R, et al. Severe community-acquired pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009;48: 377-385.
58. Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009;64:598-603.
59. Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR, et al. Validation of the Infectious Diseases Society of America/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011;53:503-511.
60. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al.; Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47:375-384.
61. Brown SM, Jones BE, Jephson AR, Dean NC; Infectious Disease Society of America/American Thoracic Society 2007. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009;37:3010-3016.
62. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, et al. Prediction of severe community-acquired pneumonia: A systematic review and meta-analysis. Crit Care 2012;16:R141.
63. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: Systematic review and meta-analysis. Intensive Care Med 2011;37:1409-1420.
64. Brown SM, Jones JP, Aronsky D, Jones BE, Lanspa MJ, Dean NC. Relationships among initial hospital triage, disease progression andmortality in community-acquired pneumonia. Respirology 2012;17:1207-1213.
65. Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 2010; 36:826-833.
66. Renaud B, Brun-Buisson C, Santin A, Coma E, Noyez C, Fine MJ, et al. Outcomes of early, late, and no admission to the intensive care unit for patients hospitalized with community-acquired pneumonia. Acad Emerg Med 2012;19:294-303.
67. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010;137:552-557.
68. Pakhale S, Mulpuru S, Verheij T, Kochen M, Rohde G, Bjerre L. Antibiotics for community-acquired pneumonia in adolescent and adult outpatients. 2014 [accessed 2017 Nov 19]. Available from: Http://www.cochrane.org/CD002109/ARI_antibiotics-forcommunity-acquired-pneumonia-in-adolescent-and-adultoutpatients.
69. English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: Comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother 2012;56:2037-2047.
70. Fogarty C, Grossman C, Williams J, Haverstock M, Church D. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748-763.
71. Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002;24:1854-1870.
72. Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24:736-751.
73. Higuera F, Hidalgo H, Feris J, Giguere G, Collins JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37: 555-564.
74. Kohno S, Watanabe A, Aoki N, Niki Y. Clinical evaluation of telithromycin for community-acquired pneumonia phase III doubleblind comparative study of telithromycin versus levofloxacin. Japanese Journal of Chemotherapy 2003;51:255-278.
75. Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, et al. A randomized, double-blind, multicenter phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of communityacquired pneumonia. J Microbiol Immunol Infect 2017;50:811-820.
76. Bonvehi P, Weber K, Busman T, Shortridge D, Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for communityacquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Investig 2003;23:491-501.
77. D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate communityacquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:4035-4041.
78. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998;41: 75-80.
79. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54: 515-523.
80. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother 2010;54:4098-4106.
81. Wiesner B, Wilen-Rosenqvist G, Lehtonen L. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia. Arzneimittelforschung 1993;43:1014-1017.
82. Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62.
83. Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013;57:2526-2534.
84. Rovira E, Martinez-Moragon E, Belda A, Gonzalvo F, Ripolles F, Pascual JM. Treatment of community-acquired pneumonia in outpatients: Randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration 1999;66: 413-418.
85. Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: A meta-analysis. Eur Respir J 2008;31:1068-1076.
86. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-195.
87. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB; Sparfloxacin European Study Group. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998;26: 1312-1320.
88. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378-386.
89. Siquier B, Sánchez-Alvarez J, García-Mendez E, SabriáM, Santos J, Pallarés R, et al.; 620 Clinical Study Group. Efficacy and safety of twicedaily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:536-545.
90. Paris R, Confalonieri M, Dal Negro R, Ligia GP, Mos L, Todisco T, et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: An open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008;20:77-86.
91. Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010;35:195-200.
92. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with communityacquired pneumonia. Arch Intern Med 1999;159:266-270.
93. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564.
94. Daneman N, McGeer A, Green K, Low DE; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management. Clin Infect Dis 2006;43:432-438.
95. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program Network, Streptococcus pneumoniae, 2016 [accessed 2019 Sept 8]. Available from: Https://www.cdc.gov/abcs/reports-findings/survreports/spneu16.pdf.
96. U.S. Food and Drug Administration. Fluoroquinolone antimicrobial drugs information. 2019 [accessed 2019 Mar 8]. Available from: Https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm346750.htm.
97. Fogarty C, Siami G, Kohler R, File TM, Tennenberg AM, Olson WH, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004;38:S16-S23.
98. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24:1292-1308.
99. Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH. High-dose levofloxacin in community-acquired pneumonia: A randomized, open-label study. Clin Drug Investig 2012;32:569-576.
100. Lin TY, Lin SM, Chen HC, Wang CJ, Wang YM, Chang ML, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007;30:321-332.
101. Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005;24: 367-376.
102. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, et al.; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372:1312-1323.
103. Xu S, Xiong S, Xu Y, Liu J, Liu H, Zhao J, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia. J Huazhong Univ Sci Technolog Med Sci 2006;26:421-424.
104. Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with b-lactams for adults with communityacquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents 2015;46:242-248.
105. Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: A systematic review. JAMA 2016;315:593-602.
106. Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:517-527.
107. Garin N, GennéD, Carballo S, Chuard C, Eich G, Hugli O, et al. b-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: A randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901.
108. Nie W, Li B, Xiu Q. b-Lactam/macrolide dual therapy versus b-lactam monotherapy for the treatment of community-acquired pneumonia in adults: A systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1441-1446.
109. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and metaanalysis. Respirology 2016;21:1193-1200.
110. File TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and safety of iv-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: The phase 3 LEAP 1 trial. Clin Infect Dis [online ahead of print] 4 Feb 2019; DOI: 10.1093/cid/ciz090.
111. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with communityacquired pneumonia: A systematic review and meta-analysis. Crit Care Med 2014;42:420-432.
112. Vardakas KZ, Trigkidis KK, Falagas ME. Fluoroquinolones or macrolides in combination with b-lactams in adult patients hospitalized with community acquired pneumonia: A systematic review and meta-analysis. Clin Microbiol Infect 2017;23:234-241.
113. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997;111:1266-1272.
114. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665-671.
115. Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia: A case-control study. J Am Geriatr Soc 1986;34:697-702.
116. Jaoude P, Badlam J, Anandam A, El-Solh AA. A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia. Intern Emerg Med 2014;9:143-150.
117. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess: Penicillin G vs clindamycin. JAMA 1975;234: 935-937.
118. Cesar L, Gonzalez C, Calia FM. Bacteriologic flora of aspirationinduced pulmonary infections. Arch Intern Med 1975;135: 711-714.
119. El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650-1654.
120. Marik PE, Careau P. The role of anaerobes in patients with ventilatorassociated pneumonia and aspiration pneumonia: A prospective study. Chest 1999;115:178-183.
121. Mier L, Dreyfuss D, Darchy B, Lanore JJ, Djedaïni K, Weber P, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia- A prospective evaluation using a protected specimen brush and quantitative cultures. Intensive Care Med 1993;19:279-284.
122. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
123. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-3862.
124. Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, et al. Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes. J Crit Care 2016; 36:265-271.
125. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, et al. Guideline-concordant therapy and outcomes in healthcareassociated pneumonia. Eur Respir J 2011;38:878-887.
126. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clin Infect Dis 2014;58:330-339.
127. Chen JI, Slater LN, Kurdgelashvili G, Husain KO, Gentry CA. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home. Ann Pharmacother 2013;47:9-19.
128. Dobler CC, Waterer G. Healthcare-associated pneumonia: A US disease or relevant to the Asia Pacific, too-. Respirology 2013;18: 923-932.
129. Ewig S, Welte T. Adding fuel to the flames- It is time to leave HCAP. Respir Med 2012;106:1309-1310.
130. Grenier C, Pépin J, Nault V, Howson J, Fournier X, Poirier MS, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011;66:1617-1624.
131. Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, Stevens VW, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized Veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 2015;61:1403-1410.
132. Kamata K, Suzuki H, Kanemoto K, Tokuda Y, Shiotani S, Hirose Y, et al. Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia. J Infect Chemother 2015;21:596-603.
133. Rothberg MB, Zilberberg MD, Pekow PS, Priya A, Haessler S, Belforti R, et al. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. J Antimicrob Chemother 2015;70:1573-1579.
134. Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drugresistant organisms in pneumonia: Moving beyond the HCAP model. Respir Med 2015;109:1-10.
135. Webb BJ, Dascomb K, Stenehjem E, Vikram HR, Agrwal N, Sakata K, et al. Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score. Antimicrob Agents Chemother 2016;60:2652-2663.
136. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: Incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-1858.
137. Cillóniz C, Gabarrús A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-acquired pneumonia due to multidrugand non-multidrug-resistant Pseudomonas aeruginosa. Chest 2016;150:415-425.
138. Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One 2015;10: E0119528.
139. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014;58:5262-5268.
140. Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, et al. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis 2011;11:61.
141. Jung WJ, Kang YA, Park MS, Park SC, Leem AY, Kim EY, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis 2013;13:370.
142. Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 2016;21:157-163.
143. Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: Differentiating characteristics and outcomes with empiric treatment. BMC Infect Dis 2014;14:252.
144. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007;101:2139-2144.
145. Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, et al. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. J Infect 2015;71:28-36.
146. Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12:153-160.
147. Rodrigo-Troyano A, Sibila O. The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology 2017;22: 1288-1299.
148. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985-995.
149. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13:268.
150. Torre-Cisneros J, Natera C, Mesa F, Trikic M, Rodriguez-Bano J. Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: A multicenter, matched case-control study. Eur J Clin Microbiol Infect Dis 2018; 37:51-56.
151. von Baum H, Welte T, Marre R, Suttorp N, Ewig S; CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010;35:598-605.
152. Wang PH, Wang HC, Cheng SL, Chang HT, Laio CH. Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drugresistant pathogens. J Formos Med Assoc 2016;115:356-363.
153. Wooten DA, Winston LG. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia. Respir Med 2013;107:1266-1270.
154. Wu HP, Chu CM, Lin CY, Yu CC, Hua CC, Yu TJ, et al. Liver cirrhosis and diabetes mellitus are risk factors for Staphylococcus aureus infection in patients with healthcare-associated or hospitalacquired pneumonia. Pulm Med 2016;2016:4706150.
155. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, et al.; GLIMP Investigators. Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): An international, observational cohort study. Lancet Infect Dis 2016;16:1364-1376.
156. Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al.; GLIMP. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients. Eur Respir J 2018;52:1701190.
157. Carugati M, Franzetti F, Wiemken T, Kelley RR, Peyrani P, Blasi F, et al. De-escalation therapy among bacteraemic patients with community-acquired pneumonia. Clin Microbiol Infect 2015;21:936, e11-8.
158. Viasus D, Simonetti AF, Garcia-Vidal C, Niubo J, Dorca J, Carratala J. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J Antimicrob Chemother 2017;72:547-553.
159. Cremers AJ, Sprong T, Schouten JA, Walraven G, Hermans PW, Meis JF, et al. Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia. J Antimicrob Chemother 2014;69: 2258-2264.
160. Yamana H, Matsui H, Tagami T, Hirashima J, Fushimi K, Yasunaga H. De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia. J Infect 2016;73:314-325.
161. Buckel WR, Stenehjem E, Sorensen J, Dean N, Webb B. Broadversus narrow-spectrum oral antibiotic transition and outcomes in health care-associated pneumonia. Ann Am Thorac Soc 2017;14: 200-205.
162. Morel J, Casoetto J, JospéR, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotherapy management: A retrospective study in a medico-surgical intensive care unit. Crit Care 2010;14:R225.
163. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanèse J, Jaber S, et al.; AZUREA Network Investigators. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014;40:1399-1408.
164. Gutiérrez-Pizarraya A, Leone M, Garnacho-Montero J, Martin C, Martin-Loeches I. Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis. Expert Rev Clin Pharmacol 2017;10: 457-465.
165. Jones BE, Brown KA, Jones MM, Huttner BD, Greene T, Sauer BC, et al. Variation in empiric coverage versus detection of methicillinresistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalizations for community-onset pneumonia across 128 US Veterans Affairs Medical Centers. Infect Control Hosp Epidemiol 2017;38:937-944.
166. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-e111.
167. Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014;58:859-864.
168. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis 2018;67:1-7.
169. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-377.
170. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-248.
171. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 2013;62:439-445.
172. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: A multicentre, double-blind, randomised, placebocontrolled trial. Lancet 2015;385:1511-1518.
173. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 2015;313: 677-686.
174. Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, et al. Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: Systematic review and metaanalysis 2015 update. Sci Rep 2015;5:14061.
175. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis. Ann Intern Med 2015;163:519-528.
176. Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, et al.; Ovidius Study Group; Capisce Study Group; STEP Study Group. Corticosteroids in patients hospitalized with community-acquired pneumonia: Systematic review and individual patient data metaanalysis. Clin Infect Dis 2018;66: 346-354.
177. Chen LP, Chen JH, Chen Y, Wu C, Yang XH. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. World J Emerg Med 2015;6:172-178.
178. Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al.; SepNet-Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: The HYPRESS randomized clinical trial. JAMA 2016;316:1775-1785.
179. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study. BMJ 2017;357:j1415.
180. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2016;3:CD010406.
181. Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010;65:510-515.
182. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al.; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568-1575.
183. Lee EH, Wu C, Lee EU, Stoute A, Hanson H, Cook HA, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010;50:1498-1504.
184. Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al.; Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517-1525.
185. Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012;55:1198-1204.
186. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet 2015;385:1729-1737.
187. Venkatesan S, Myles PR, Leonardi-Bee J, Muthuri SG, Al Masri M, Andrews N, et al. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: An individual participant data metaanalysis. Clin Infect Dis 2017;64:1328-1334.
188. Metersky ML, Masterton RG, Lode H, File TM, Jr., Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012; 16:e321-e331.
189. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): Pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010;177:166-175.
190. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12:894-899.
191. Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infect Dis 2010;50:e59-e62.
192. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 2012;205:895-905.
193. Rodríguez AH, Avilés-Jurado FX, Díaz E, Schuetz P, Trefler SI, Solé-Violán J, et al.; SEMICYUC/GETGAG Working Group. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. J Infect 2016;72:143-151.
194. el Moussaoui R, de Borgie CA, van den Broek P, Hustinx WN, Bresser P, van den Berk GE, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderatesevere community acquired pneumonia: Randomised, double blind study. BMJ 2006;332:1355.
195. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: A prospective, randomized, double-blind study. Am J Ther 1999;6:217-222.
196. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003;37:752-760.
197. Leophonte P, Choutet P, Gaillat J, Petitpretz P, Portier H, Montestruc F, et al. Efficacitécomparée de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aigues communautaires de l'adulte hospitaliséavec facteur de risque [in French]. Med Mal Infect 2992;32:360-381.
198. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia : A meta-analysis. Drugs 2008;68:1841-1854.
199. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: A metaanalysis. Am J Med 2007;120:783-790.
200. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for communityacquired pneumonia in adults. Antimicrob Agents Chemother 2018; 62:e00635-18.
201. Krüger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, et al.; CAPNETZ Study Group. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: Results from the German competence network CAPNETZ. Respir Res 2009;10:65.
202. Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, Machado MB, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: A prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care 2014; 18:R44.
203. Musher DM, Bebko SP, Roig IL. Serum procalcitonin level, viral polymerase chain reaction analysis, and lower respiratory tract infection. J Infect Dis 2014;209:631-633.
204. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines. JAMA 1998;279:1452-1457.
205. Zasowski E, Butterfield JM, McNutt LA, Cohen J, Cosler L, Pai MP, et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Antimicrob Agents Chemother 2014;58:3804-3813.
206. Garin N, Felix G, Chuard C, GennéD, Carballo S, Hugli O, et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One 2016;11:e0157350.
207. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, et al.; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: Implications for disease outcome. Thorax 2004;59:960-965.
208. Menéndez R, Torres A, Rodríguez de Castro F, Zalacaín R, Aspa J, Martín Villasclaras JJ, et al.; Neumofail Group. Reaching stability in community-acquired pneumonia: The effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-1790.
209. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with communityacquired pneumonia: Causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-160.
210. Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, et al. Duration of antibiotic treatment in community-acquired pneumonia: A multicenter randomized clinical trial. JAMA Intern Med 2016;176:1257-1265.
211. Macdonald C, Jayathissa S, Leadbetter M. Is post-pneumonia chest X-ray for lung malignancy useful- Results of an audit of current practice. Intern Med J 2015;45:329-334.
212. Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: The value of convalescent chest radiography and follow-up. Scand J Infect Dis 1993;25:93-100.
213. Little BP, Gilman MD, Humphrey KL, Alkasab TK, Gibbons FK, Shepard JA, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. AJR Am J Roentgenol 2014;202:54-59.
214. Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med 2011;171:1193-1198.
215. Mortensen EM, Copeland LA, Pugh MJ, Fine MJ, Nakashima B, Restrepo MI, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med 2010;123:66-71.
216. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:330-338.